Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms

Abstract

Ospemifene is an effective potential therapy for postmenopausal women with VVA improving OAB symptoms and quality of life.

A medical device containing purified bovine colostrum (Monurelle Biogel) in the treatment of vulvovaginal atrophy in postmenopausal women: Retrospective analysis of urinary symptoms, sexual function, and quality of life

“…The findings of the present study support the effectiveness and safety of purified bovine colostrum (Monurelle Biogel) in improving (VVA), sexual function, urinary symptoms, and QoL in postmenopausal patients with GSM. Large cohort studies have reported the prevalence of vaginal dryness in postmenopausal women of 27% to 55% and a prevalence of dyspareunia of 32% to 41%, but with early identification, treatment can improve these symptoms and reverse the physical changes . Local estrogen therapy is the first line recommended treatment, more effective than systemic therapy, to alleviate subjective symptoms of atrophy in healthy postmenopausal women without VMS .…”

“…Menopause is a physiological condition associated with estrogen deficiency, inducing vaginal and vulvar dryness, commonly known as vulvovaginal atrophy (VVA) . Vaginal dryness reduces lubrication during sexual intercourse, resulting in pain and other female sexual dysfunctions (FSD), and may interfere with simple activities such as walking or exercising, compromising quality of life (QoL) . Estrogen deficiency may also be associated with lower urinary tract symptoms (LUTS) such as dysuria, urethral discomfort, overactive bladder (OAB) symptoms, and stress or urge urinary incontinence .…”

Recent advances in managing overactive bladder

“…There were also significant improvements in OAB questionnaire scores. A retrospective review of 46 women using ospemifene for GSM found a significant improvement in frequency, nocturia, urgency, and urgency incontinence 30 .…”

Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause

“…Another study showed that 6 months of ospemifene significantly reduced recurrent UTIs in 39 women with GSM; these women also had improvements in sexual function with ospemifene [80]. A retrospective analysis found that 12 weeks of ospemifene significantly reduced urgency and other overactive bladder symptoms in postmenopausal women with VVA (n = 46) [81]. Further study of ospemifene as a potential treatment for the urinary component of GSM is warranted.…”